ROME — Italian Prime Minister Giorgia Meloni used a message to Farmindustria’s 2026 annual assembly to frame the pharmaceutical sector as a pillar of national health, economic growth and strategic autonomy, while highlighting the government’s plan to complete a long-awaited overhaul of pharmaceutical legislation.
The intervention comes as European governments increasingly link health security, industrial competitiveness and technological sovereignty to domestic pharmaceutical production and innovation.
Why it matters: Rome is positioning pharmaceuticals as a strategic industry alongside broader efforts to strengthen economic resilience and technological autonomy.
- The government is signaling regulatory reform aimed at improving competitiveness and attracting investment.
- Meloni linked pharmaceutical innovation to national security, a theme that has gained prominence across Europe since the pandemic and amid geopolitical tensions.
- The sector remains one of Italy’s strongest export-oriented industries and a key component of the country’s life sciences ecosystem.
The big picture: In her message to the assembly, Meloni described pharmaceuticals as “one of the absolute excellences of Made in Italy” and a strategic sector for “the health, growth and security of the nation.”
- She argued that the industry embodies three interconnected forms of value: innovation, research and security.
- According to Meloni, innovation improves citizens’ health and quality of life, research advances medical treatments, and security strengthens the country’s technological sovereignty and resilience.
- The message reflects a broader government narrative that increasingly connects industrial policy with strategic autonomy and national competitiveness.
Zoom in: The pharmaceutical reform. The most concrete policy signal in Meloni’s remarks concerned the government’s work on a new consolidated pharmaceutical law.
- She described the planned “Testo Unico della legislazione farmaceutica” as a reform “awaited for decades” and said the government is working “with great determination” to bring it to completion.
According to Meloni, the reform is intended to:
- simplify the regulatory framework;
- provide greater certainty for industry operators;
- accelerate access to innovation;
- help Italy remain competitive amid technological shifts, including artificial intelligence and new therapeutic platforms.
- The government presents the measure as a tool to strengthen both industrial competitiveness and patient access to new treatments.
Between the lines: Meloni’s intervention suggests that Rome sees life sciences not only as a healthcare issue but also as an industrial and geopolitical asset.
- “Investing in life sciences means investing in one’s own strategic autonomy,” she said, linking the sector directly to broader questions of resilience and national capability.
- The message also underscores the government’s effort to make Italy more attractive for investment while preserving its industrial leadership in pharmaceuticals.
The bottom line: Meloni used the Farmindustria assembly to reinforce a central theme of her government’s economic strategy: pharmaceutical innovation is no longer framed solely as a health policy priority, but as a strategic asset tied to competitiveness, technological sovereignty and national resilience. The planned pharmaceutical reform is emerging as a key instrument in that agenda.
